The global tinea pedis treatment market is estimated to be valued at USD 1,496.3 million in 2024. Global demand will likely increase at 5.2% CAGR, with total industry size reaching USD 2,484 million by 2034.
Antifungals remain the most preferred drugs to treat tinea pedis. The target segment accounted for a revenue share of 71.8% in 2023. Antifungal medications specifically target the fungi responsible for causing tinea pedis infections, such as dermatophytes like Trichophyton rubrum and Trichophyton mentagrophytes.
By inhibiting fungal growth or killing the fungi outright, antifungals effectively treat the underlying cause of the infection, providing symptomatic relief and promoting healing. These medications are gaining popularity due to their targeted action.
Several factors are expected to stimulate the growth of the tinea pedis market during the assessment period. These include the escalating prevalence of fungal infections like tinea pedis, growing health awareness, and the development of novel antifungal medications.
Tinea pedis is one of the most common fungal infections globally, affecting individuals of all ages and demographics. The prevalence of tinea pedis varies across regions, with higher rates often observed in warm and humid climates where the environment is conducive to fungal growth.
Countries with high population densities, inadequate sanitation facilities, and limited access to healthcare are experiencing a higher burden of tinea pedis infections. The widespread prevalence of tinea pedis, influenced by factors such as gender, age, and lifestyle habits, serves as a key driver for the tinea pedis treatment market.
As the incidence of tinea pedis continues to grow globally, so will demand for tinea pedis treatment. Patients with tinea pedis often opt for antifungals and other medications to relieve symptoms and cure this fungal infection.
Advances in medical research and technology are allowing companies to develop more effective and convenient treatment solutions. This will further boost industry growth during the assessment period.
Key Takeaways from the Market Study:
- The global tinea pedis treatment industry is set to advance at 2% CAGR through 2034.
- By disease indication, the interdigital tinea pedis is forecast to account for a share value of 4% in 2024.
- By route of administration, the topical segment will likely hold a value share of 4% in 2024.
- By distribution channel, the hospital pharmacies segment is anticipated to hold a market share of 4% in 2024.
- By drug class, the antifungal category dominates the market, accounting for 8% of the market share value in 2023.
- The United States is poised to exhibit a CAGR of 2% through 2034.
- Demand in China is predicted to increase at 3% CAGR between 2024 and 2034.
“Medical research has fuelled the creation of potent topical antifungal creams and ointments specifically tailored to combat tinea pedis. Development of these new enhanced formulations will bode well for the industry during the assessment period,” says a lead analyst of Future Market Insights (FMI).
Find the Latest Updates on Get Old Source Reports…
Who is Winning?
Glenmark Pharmaceuticals Inc., USA, McKesson (NorthStar Rx LLC), Camber Pharmaceuticals, Inc., Sebela Pharmaceuticals, Inc., Blueberry Therapeutics Ltd., Exeltis USA, Inc., Viatris (Mylan N.V.), Bayer AG, GlaxoSmithKline Plc (GSK), and Novartis AG are few of the leading players listed in the report.
Top companies are constantly striving to develop new antifungal medications with enhanced antifungal activity, reduced side effects, and improved skin compatibility. They are also implementing strategies like acquisitions, distribution agreements, and partnerships to stay ahead of the competition.
Industry Updates:
- In January 2024, Sun Pharmaceutical Industries Limited and Taro Pharmaceutical Industries Ltd. entered into a definitive merger agreement.
- In September 2023, Aurobindo Pharma announced that it was entering the Indonesian market by acquiring 15 formulation brands from Pfizer Inc. and Viatris Inc.
Key Segments of Market Report:
By Disease Indication:
As per disease indication, the industry has been categorized into interdigital tinea pedis, plantar tinea pedis, and vesicular tinea pedis.
By Route of Administration:
Based on route of administration, the report is segmented into topical and oral. The topical segment is further divided into gel, cream, spray, lotion, and powder.
By Distribution Channel:
Different distribution channels include hospital pharmacies, retail pharmacies, drug stores, and online pharmacies.
By Drug Class:
In terms of drug class, the industry is categorized into antifungals and combinations.
By Region:
Industry analysis has been carried out in key countries of North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East and Africa.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube